In the analysis of the screening data from the British Columbia cohort study, a considerable amount of regression was found. The regression is concentrated in lesions detected at younger ages (Boyes et al., 1982) . This finding was based on a comparison of the estimated cumulative incidence of pre-invasive lesions with the prevalence of these lesions and with the cumulative incidence of clinically diagnosed invasive cervical cancer. However, no explicit hypotheses about regression were tested. A model based approach would allow for using the details age-specific data from the cohort study in testing the assumptions. Earlier modelling efforts, e.g. by Coppleson and Brown (1975) Columbia, but only on a very limited scale. The impact on clinical incidence in the first years of screening has presumably been negligible. Thus, the incidence in 1955-57 is considered to represent the situation without screening. We converted the clinical incidence into an incidence rate for the female population at risk of cervical cancer by correcting for the cumulative hysterectomy rates recorded in the two cohort study populations.
Regression of pre-invasive cervical cancer is still a controversial issue. The possibility of regression, which may not occur at the same rate at all ages, is important for decision making about screening policies and about management of these lesions. A high regression rate would mean that many screendetected lesions are diagnosed and treated unnecessarily. This would influence the balance between favourable and adverse effects of screening.
In the analysis of the screening data from the British Columbia cohort study, a considerable amount of regression was found. The regression is concentrated in lesions detected at younger ages (Boyes et al., 1982) . This finding was based on a comparison of the estimated cumulative incidence of pre-invasive lesions with the prevalence of these lesions and with the cumulative incidence of clinically diagnosed invasive cervical cancer. However, no explicit hypotheses about regression were tested. A model based approach would allow for using the details age-specific data from the cohort study in testing the assumptions. Earlier modelling efforts, e.g. by Coppleson and Brown (1975) also pointed at the existence of regression, but used a combination of data from widely different sources.
For breast cancer, Day and Walter (1984) proposed a simplified model that can be used in analysing data from screening programs. In this paper we propose a simplified model for cervical cancer, and use the model to test hypotheses about regression against data from the screening program in British Columbia.
A model for cervical cancer is more complicated than for breast cancer, because of the long duration of pre-invasive stages and the possibility of regression. The proposed model contains the essentials of screening for cervical cancer: incidence of pre-invasive lesions, duration, progression and possible regression of these lesions, and sensitivity of the Pap smear.
Three hypotheses about regression of pre-invasive lesions are tested: (A) no regression, (B) a constant rate of regression at all ages, and (C) different regression rates for lesions that occur in young and middle-aged women, respectively.
Material and methods
The data used in testing the hypotheses are all derived from the report of the British Columbia cohort study (Boyes et al., 1982) . This study analysed the records of the screening program in British Columbia in the period 1949-1969, for two cohorts of women, born in 1914-18 and 1929-33, respec- tively. A full overview of the data is presented in Appendix A, Table A-I.
The age-specific incidence of clinical cervical cancer is based on data for the total female population between ages 20-24 and 60-64 in British Columbia in 1955-1957 . Cervical cancer screening started already around 1950 in British Columbia, but only on a very limited scale. The impact on clinical incidence in the first years of screening has presumably been negligible. Thus, the incidence in 1955-57 is considered to represent the situation without screening. We converted the clinical incidence into an incidence rate for the female population at risk of cervical cancer by correcting for the cumulative hysterectomy rates recorded in the two cohort study populations.
A distinct advantage of the data from British Columbia is that age-specific rates are available over a broad age-range, both for clinically diagnosed cancers and for screen-detected lesions. The two cohorts together span the age-range 20-54 in the study period. In the overlapping age-group 35-39, results from the younger cohort are used because of the larger numbers in this group. It is assumed that the crosssectional clinical incidence data and the longitudinal screening data are comparable. Differences between these data sets could be caused by cohort effects, but cohort differences were not found in the cohort study (Boyes et al., 1982) .
Regression is supposed to occur only in pre-invasive lesions. The observed detection rates of pre-invasive lesions (dysplasia and carcinoma in situ) of a first smear are included in estimating and testing the assumptions about regression (see Table A -I). In the results of the second and subsequent smears, the pre-invasive and early invasive lesions are pooled, because of the small numbers in the latter category. On basis of the tables in the report of the cohort study, these results are classified by age at midpoint between the first and second smear, and by the time since the preceding Pap-smear.
The clinical incidence rates in the unscreened parts of the cohorts are also used in testing the model. An important reason for including these data in the analysis is that they contain information about the difference in potential risk for Correspondence: G.J. van Second, the pre-invasive duration is described by a Weibull probability distribution which has two parameters: mean duration m and shape (or concentration parameter) b. The Weibull distribution is a generalisation of the exponential distribution. The additional concentration parameter allows for changing the variance in the duration independently from the mean, higher values indicating less variability.
Third, the duration of the preclinical invasive stage and the sensitivity in this stage are assessed directly from the clinical Figure 1 Schematic representation of the model. incidence rates and detection rates of the first smear, see The Likelihood-Ratio test is used to compare the models A, B and C, and also in finding one-and two-dimension confidence regions for the parameters. More specific details on the estimation and testing procedures are given in Appendix B.
Results
The best fitting parameter values for the three models (A, B and C) are presented in Table I . The goodness-of-fit test for the assumption that all pre-invasive lesions will progress to become invasive cancers (model A) shows that it is not possible to fit the data from British Columbia with this assumption. Especially the results of second and subsequent smears show large discrepancies between observed data and the model (See Appendix A, Table A-I). The clinical incidence and the detection rate of the first screen are fitted fairly well. This obviously required quite surprising parameter estimates: a very long average duration (33 years) of preinvasive lesions, coupled with an incidence rate of 1.3 x 10-3 between age 15 and 33 which is much higher than the clinical incidence rate. After age 33, few pre-invasive lesions start developing. Because of the low estimate (66%) for the sensitivity of the Pap smear, the model gives too high detection rates for smears made within a short interval after the preceding smear. And the relatively low incidence rate of new lesions results in much too low detection rates for smears made after an interval of more than 3 years since the first or second smear.
With a shape parameter of 2.1 the variability in duration is rather low, and only 24% of the pre-invasive lesions will have a duration of less than 20 years. In other words: although no explicit regression is assumed in model A, this very long duration, with a considerable amount of (very) slow-progressing lesions, can be interpreted as a compensating mechanism.
The assumption of an equal proportion regression at all ages (model B) results in an estimate of 53% for the proportion regression among pre-invasive lesions, see Table I . The estimates for the onset after age 33, the mean duration of pre-invasive lesions, and the sensitivity of the Pap smear differ considerably from the case with no regression (model A). Although model B gives a statistically significant (P<0.0001) better fit than model A, the goodness of fit test against the cohort study data still yields a P-value smaller than 0.01. The same discrepancies with observed data found in model A exist in model B; they are only less extreme.
The difference in log-likelihood between the model (A) with no regression and the model (C) with age-dependent regression indicates that a clearly significant (P<<0.0001) improvement is brought about by adding age-dependent regression. Moreover, model C gives a good fit of the observed data from British Columbia. Between age 18 and 34, the incidence of pre-invasive lesions is high, and the estimated proportion of regression among these lesions is 84%. The proportion regression over age 34 is 40%. From all lesions developing before age 65, an average of 62% is regressive. Estimates for the other parameters show considerable differences compared to the case with no regression (model A, see Table I ). In women older than 34 years, there is a substanial onset rate of new pre-invasive lesions. The estimates for the duration of pre-invasive lesions imply that the large majority (85%) of the new progressive lesions will turn into invasive lesions within 20 years. In combination with the higher sensitivity (0.80) of the Pap smear, these changes lead to a considerable improvement in the fit of the detection rate of second and subsequent smears. The relative risk of participants is 0.74, indicating that unscreened women constitute a high risk group.
For model (C), assumptions about average duration, sensitivity, progression rate, and the shape have been varied to find 95% confidence limits for these parameters, see Table II . The mean duration of pre-invasive lesions is between 9.8 and 14.4 years. Mean durations of less than 9.8 years result in clinical incidence rates becoming too high at older ages, durations longer than 14.4 years will conversely result in too high detection rates at older age. The range for the shape parameter of the distribution means that the standard deviation is between 5.9 and 12.1 years. The sensitivity of the Pap smear for pre-invasive lesions is between 76% and 85%. Other values will especially deteriorate the fits of detection We also considered alternative values for the ages (ao and a,) at which the onset rate and progression change. The confidence range for the age at which the onset starts is from 17 to 20 years, and the onset changes between ages 32 and 36. Outside both confidence ranges the fit deteriorates rapidly. Note that in Table 18 in Boyes et al. (1982) already a clear difference was shown between estimated incidence rates of dysplasia before and after age 35.
Only slightly wider ranges are found when two-dimensional confidence regions are considered, see Figure 2 . For example, even when the sensitivity would be known to be 77%, then the upper limit for progression is still only 27%. From the figure it can be seen that variation in one parameter may be compensated by changing other parameters as well. For example, a high proportion of regression is possible when the onset rates are high, the mean duration short, and the sensitivity high. 
Discussion
In the original analysis of the British Columbia cohort study, it was concluded that regression is part of the natural history of dysplasia and carcinoma in situ, and that regression is more likely to occur at younger ages (Boyes et al., 1982 (34) . Thus, the model should be regarded as a filtered version of a more smoothly operating process.
Both the sensitivity and the duration of pre-invasive lesions are assumed to be independent from age. Possibly, there could be more fast growing lesions at increasing age, but testing assumptions about age-dependent duration is hampered by the absence of screening data from age 54 onwards. It is difficult to predict the consequences of such assumptions for the estimated proportion regression, because of the confounding effects of other parameters that will also take different values (as could be seen in Figure 2) .
The average duration of regressive and progressive preinvasive lesions is assumed to be equal. A shorter duration for regressive lesions would probably result in an even higher proportion of (new) regressive lesions.
In model (C) with age-dependent regression, the confidence interval for the concentration parameter governing the variability in the duration of pre-invasive lesions includes the value b = 1.0 which represents an exponential distribution (see Table II (Koopmanschap et al., 1990b) . The decision to include the relative risk parameter in the model was supported by the clearly higher clinical incidence rates in the unscreened parts of the cohorts in comparison with the clinical incidence in the total population in the 'unscreened' situation in 1955-57. It was noted by Boyes et al. (1982) that the acuracy of the clinical incidence rates in the cohorts may suffer from problems in determining the actual size of the unscreened 'at-risk' population. However, if these data are not used in the estimation procedure, and the relative risk is given a fixed value assuming either no difference in risk between participants and unscreened women or a relative risk of 0.8 for participants, the resulting parameter estimates are still within the confidence ranges for the full model C as presented in Table II (Anderson et al., 1988) . Given the tendency towards treatment of very early abnormalities, and the impossibility to discern regessive from progressive lesions, it seem probable that the proportion of regressive lesions among those treated after detection by screening will become larger as a result of these develop-ments.
Estimates for the proportion regression based on follow-up of untreated cases of carcinoma in situ show great variations, see Brinton (1986) for an overview. For carcinoma in situ lesions, Kottmeier (1961) reported 71% progression to invasive cancer after 12 years of follow-up. In contrast to this figure is the 36% regression after 5 years of follow-up, as reported by Kinlen and Spriggs (1976) . They also found that regression was confined to women aged less than 40 at the time of the initial smear. These follow-up periods are short if compared with the duration of preinvasive stages. The principal value of these studies is thus the support for the existence of spontaneous regression.
Our estimate that a considerable proportion of pre-invasive lesions will progress to invasive stage does not prove a causal relation between dysplasia and carcinoma in situ and invasive cervical cancer. Evidence for such a relation is given by the results of a combined analysis of data from major screening programmes (IARC Working Group, 1986) , indicating a strong reduction in risk of invasive cervical cancer in the first 5-10 years after one or more negative Pap smears. We have analysed the IARC data with model C, using the quantification given in Table I . Despite the apparent difference between the long average duration of 11.8 years and the relatively short duration of the protective effect reported by the IARC study, we found that the model gives a good fit of this reduction in risk (Van Oortmarssen & Habbema, 'Long mean duration of pre-clinical stages of cervical cancer and short protection by Pap smears: a reconciliation of two epidemiological approaches', submitted for publication).
Among the models for evaluation of cervical cancer screening (see Prorok (1986) for an overview), a number of other 'simplified' models for analysis of screening data have been published. Coppleson and Brown (1975) use data on age specific clinical incidence and detection rates of a first smear. This is a much more limited data set than we used, and their model shows some differences with our model. However, they also found that the possibility of regression should be included in the model in order to explain the observed data. Albert (1981) tried to fit annual data concerning number of cases with CIS, pre-clinical invasive, and clinical invasive cancer in British Columbia. No distinction is made between first and subsequent smears, and false negatives are neglected. In our opinion, too many important aspects (age-dependencies, differences between first and subsequent smears) are neglected in this model, and it is not suited for testing assumptions about regression of CIS. Brookmeyer and Day (1987) proposed an extension of the model that Day and Walter developed for breast cancer screening, which is similar to our extension. They analysed data from a case-control study addressing the question of the relative risk of invasive cancer for women who had a negative smear from. The data come from one of the screening programmes involved in the IARC study (IARC working group (1986)) . Detection rates at successive smears are not taken into account, and therefore the proportion of regression cannot be estimated from these data. The sensitivity of the Pap smear and the mean duration of the pre-clinical stage are estimated and have a large confidence region that includes our estimates. Gustafsson and Adami (1989) used a model that is similar to ours, but includes mortality as an additional final stage. Swedish population based incidence (CIS and invasive cancer) and mortality rates are used to obtain estimates for regression and duration of the preclinical stages. The estimated mean duration of the pre-invasive stage is 13.3 years, which compares well with our estimate: Further similarities are found for the variability of the duration (40% of new lesions will become invasive within 10 years, compared to 47% in our model) and the mean duration (3.9 years) of pre-clinical invasive lesions. However, the proportion progressive lesions is estimated to be lower (12%) than in our model, and is found to be independent from age, resulting in a marked difference with our model at higher ages. This low proportion might be due to the fact that in analysing of the Swedish data, no distinction could be made between results of first and subsequent smears, see van Oortmarssen and Habbema (1990) and Adami and Gustafsson (1990) .
Other models for cervical cancer screening are comprehensive rather than simplified, and try to give a realistic description of the processes involved. Such models are less useful for estimation of parameters or testing of hypotheses. Typically, these models aim at evaluation of different screening policies (Knox, 1973; Eddy, 1981) .
We conclude that the present analysis gives evidence for the existence of a considerable proportion of regression, especially at young ages. The implications of this finding for cervical screening policies can best be considered in a costeffectiveness framework. Such as analysis, based on this and other model-based analyses of screening data has been carried out for the present situation regarding the epidemiology and early detection and treatment possibilities for cervical cancer. The medical findings are reported in van Ballegooijen et al. (1990) , and the economic aspects in Koopmanschap et al. (1990a) . The results point out that frequent screening at young ages gives rise to an unfavourable balance between favourable and adverse effects. It is also inefficient when comparisons of the cost-effectiveness ratio are made with screening at higher ages.
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APPENDIX A Table A -I Overview of the data from the British Columbia cohort study (Boyes et al., 1982) , and the fit between expected numbers for models A, B, C and observed numbers Observed data Expected number of cases Age Rate x 10-' Cases Model A Model B Model C Appendix B
The formulae of the model.
In this appendix, we will give the formulae that have been used in calculating the expected incidence rates and detection rates as shown in Table A . 1, on basis of the ten parameters of the model: ao, a,, rl, r2, rr, m, b, pl, P2, sp (see Table I ).
Functions jz) and F{z) are the probability density and distribution, respectively, of the duration z of the pre-invasive stage. The Weibull distribution for F(z) is characterised by two parameters, scale c and shape b:
The scale parameter c can be obtained from the mean m, since m = c r(1 + 1/b), where r() is the Gamma function. The probability density and distribtuion functions for the duration y = z + q of the total preclinical state is denoted by g(y) and G(y), respectively, where q is the duration of the preclinical invasive stage. The clinical incidence I(a) at age a is derived from the onset rate R(a-y), the proportion of progressive lesions p(a-y) and the distribution g(y) of the total duration y = z + q of the two pre-clinical stages:
The clinical incidence applies to the total female population at risk, which by definition has a relative risk equal to 1.0. For known values of the relative risk rr of the screened population, the relative risk of the unscreened population ru(a) is age-dependent via the fraction screened x(a):
ru(a) = I-x(a).rr (3) The incidence in the unscreened part of the cohorts is ru(a).I(a) and can be derived from expression (2) and (3). For convenience, we introduce N(a), the rate at which cases leave the pre-invasive stage: And the detection rate of invasive pre-clinical lesions: a
The detection rate of pre-clinical lesions for a second smear at age u2 depends on the age u, at which the first smear was made.
The notation (1-_Sp)a<u1 is used to indicate that the false negative rate at the first screening should be taken into account only in cases where the onset occurred before age u,. For the detection rates of second and later smears, a further simplifying assumption was made to reduce numerical complexity: the fast negative rate at the subsequent smear(s) is assumed to be 1.0-sp for all screen-detectable lesions. Thus, the expression for the false negative rate is an approximation, neglecting the lower false negative rate 1.0-se in cases who are in stage preclinical invasive already at age u2. This will result in a slight exaggeration of the detection rate, since lesions that are in stage pre-clinical invasive cervical cancer at preceding smears would have a false negative rate of u2.
The detection rate at a third screen at age u3 depends on the ages u, and u2 of the preceding smears: Expressions (2), (5), (7) and (8) can now be simplified considerably. The resulting expressions are used to calculate expected rates for a given set of parameter values. The clinical incidence I(a) and the detection rate of a first smear are calculated for 1-year age-groups and then aggregated to the classes used in the testing procedure. The detection rates S(uj,u2) of a second smear are calculated for a matrix of 'ages at mid-point of the interval' and intervals. The same method is used for detection rates T(u,u2,u3) of third and subsequent smears, assuming that the interval between the first and second smear is 1, 2, 3 or 5 years with probabilities 0.40, 0.30, 0.15 and 0.15, respectively (based on women years in the published tables for the second smear). These rates are also aggregated, after dividing the rates by the lengh of the interval to obtain rates that have women-years as denominator. Expected numbers of cases are obtained by multiplying expected rates and observed denominators (women-years or number screened). The log-likelihood is based on the assumption that the observed cases are a realisation of a Poisson-distribution with mean = expected number of cases. The likelihood is maximised using a downhill simplex multidimensional optimisation routine (Press et al., 1988) . The total number of classes is 45, the number of degrees of freedom for the Pearson Chi-Square test for the goodness of fit of the model is 41 minus the number of free parameters that were varied in deriving the maximum likelihood estimates. The number of degrees of freedom equals the number of categories minus 4, since in each cohort both expected and observed sum of cases detected with the second smear and with subsequent smears is the same for the two subclassifications (by age and by interval since first smear), as can be seen in Table A -I. The deviance, i.e. the likelihood ratio test statistic for comparing a model with the complete model, is also inspected in assessing the goodness of fit.
Comparisons between models are based on the Likelihood-ratio test. Also, 95% confidence regions for one and for two parameters are obtained by inverting the Likelihood-ratio test, i.e., by searching for parameter values for which the lbg likelihood is 3.84 . 2 respectively 5.99 * . 2 lower than the log-likelihood of the optimal model. One-and two-dimensional confidence regions (Table II, Figure 2 ) are computed by repeatedly applying the downhill simplex optimisation routine in combination with a root-finding algorithm.
